【摘要】 目的比较齐拉西酮和奥氮平对首发精神分裂症的疗效和安全性。方法 260名病人被随机分配到两组进行为期6周的药物治疗。使用阳性和阴性症状量表(PANSS)和临床总体印象-疾病严重程度量表(CGI-S)评定药物的主要疗效。使用不良事件记录表的记录与药物相关的不良反应。结果共有245名患者完成研究,齐拉西酮组平均剂量137.5mg/d,奥氮平组19.5mg/d。奥氮平组PANSS评分的改善显著优于齐拉西酮组(P<0.05),而CGI-S评分在两组间的差异无显著性(P>0.05)。两种药物的耐受性均较好,齐拉西酮组有QTc间期延长和锥体外系副反应(EPS),奥氮平组有显著的体重增加(组间比较P<0.05)。结论虽然奥氮平对首发精神分裂症的短期疗效要优于齐拉西酮,但齐拉西酮几乎不会引起体重增加。在临床用药中需综合考虑两种药物的优劣。更多还原

【Abstract】 Objective To compare the efficacy and safety of Ziprasidone versus Olanzapine in first-episode schizophrenia.Methods 260 patients were randomly assigned to treatment for 6 weeks either with ziprasidone or Olanzapine.The primary efficacy measurement was the change of Positive and Negative Syndrome Scale(PANSS) and the Clinical Global Impression-severity scale(CGI-S) scores from baseline to the end of study.The adverse events(AEs) were recorded by the investigator.Results 245 patients completed the trial.The average dose was 137.5mg/d in the Ziprasidone group and 19.5mg/d in the Olanzapine group.The Olanzapine group showed significantly more improvement than the Ziprasidone group on the PANSS tatol score.No significant differences were found between the two groups in CGI-S score.Both agents were well tolerated.Prolongation of QTc and extrapyramidal symptoms were more significant in Ziprasidone group than in Olanzapine group.Body weight significantly increased with Olanzapine but not with Ziprasidone.No serious AEs were observed in this study.Conclusion Althought Olanzapine is more effective than Ziprasidone in the short-term treatment of first-episode schizophrenia,ziprasidone almost does not induce weight gain.Both the advantages and disadvantages of the two agents should be considered in the clinical selection.更多还原